12,372 trials
Non-Proliferative Diabetic Retinopathy · Cataract
Primary: Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90…
Erythema · Rosacea
Primary: Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for…
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. — 47; 16…
Chronic Idiopathic Constipation
Primary: Time Reduction (Hours and Minutes) of Gastric Emptying (GE), Small Bowel (SB), Large Bowel (LB) and Whole Gut (WG) Transits Measured by SmartPill in Chronically…
Erectile Dysfunction · Lower Urinary Tract Symptoms
Primary: Change From Baseline Erectile Function Domain of the International Index of Erectile Function — 2.84; 2.84 Change in EF Domain Score from Baseline
Asthma
Primary: Mean Growth Rate in Lower-leg Growth, as Determined by Knemometry. — 0.3638; 0.3118 millimeter per week
Acute Liver Failure · Hepatic Encephalopathy
Primary: Survival — 68; 76 Participants — p=0.19
Anemia
Primary: Percentage of Participants Who Maintained Average Hb Value Within Target Range During the EEP — 50.0 percentage of participants
Paroxysmal Atrial Fibrillation
Primary: Chronic Effectiveness in Treating PAF as Demonstrated by no AF Recurrences After the Blanking Period and During the 12-month Follow-up Period. — 42 Successful participants
Prostate Cancer · Sexual Dysfunction
Primary: Percentage of Patients Maintaining Spontaneous (Off-drug) Erectile Function (EF) at Weeks 28-30 After Initiation of Radiation Therapy (RT) — 79; 74 percentage of…
Bipolar I Disorder
Primary: Time to Recurrence of Mood Event During the Double Blind Treatment Phase — NA; 207 Days — p=<0.078
Leukaemia, Lymphocytic, Chronic
Primary: Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC) — 28.94; 18.83 Months — p=0.0032
Breast Cancer · Fatigue · Sleep Disorders
Primary: Change in Cognitive Function Over 1 Year in Premenopausal Breast Cancer Patients Who Receive Adjuvant Tamoxifen (T) Alone Against Those Receive Adjuvant Tamoxifen…
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Phase A, FAS Population) — -0.49; -0.10 Percent — p=<0.001
Anemia
Primary: Mean Change in Hb Concentration Between Baseline and the Efficacy Evaluation Period — 1.99 g/dL